6-8
Oct
2026
CPHI Milan 2026
Fiera Milano, Italy
7A34
23-25
Nov
2026
CPHI India 2026
IICC, Yashobhoomi, Dwarka, Delhi
1D16
14-16
Dec
2026
CPHI Middle East 2026
Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
H1.V90

MSN Laboratories

About MSN Laboratories

MSN Laboratories was founded in 2003 and is one of the fastest growing pharmaceutical manufacturers of APIs and finished dosages in India. We have Nine API and Five Finished dosage facilities & an integrated R&D Center located in Hyderabad.

Our state-of-the-art facilities are accredited by  USFDA, EU:GMP, WHO:Geneva, PIC/S, ANVISA, Invima and many other global approvals. With a product portfolio covering 35 major therapies including Oncology, MSN reaches out to millions of people in 65 countries across North America, Europe, Latin America, CIS, Middle East, Africa & Asia.  

Our strengths are our world-class facilities, innovation dri...

Meet us at

  • CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
  • CPHI India 2026

    IICC, Yashobhoomi, Dwarka, Delhi
    23 Nov 2026 - 25 Nov 2026
  • CPHI Middle East 2026

    Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
    14 Dec 2026 - 16 Dec 2026
  • Country/Region:
    India
  • On CPHI since:
    2015
  • Employees:
    5000+
Company types
Manufacturer/Innovator
Contact info

Products from MSN Laboratories (27)

  • Complex Peptides

    Product Complex Peptides

    Growing capabilities in complex peptides, combining advanced expertise, quality-focused processes and reliable support for pharmaceutical partners
  • Iron Complexes

    Product Iron Complexes

    Specialized capabilities in iron complexes, supported by strong chemistry expertise and a commitment to quality and reliable supply.
  • Organic Synthesis

    Product Organic Synthesis

    Strong organic synthesis capabilities enabling the development of diverse and complex pharmaceutical molecules with quality at every stage.
  • Achiral Chemistry

    Product Achiral Chemistry

    Established achiral chemistry capabilities supporting diverse pharmaceutical development and manufacturing requirements.
  • Ampoules

    Product Ampoules

    Ampoule-based injectable solutions supported by robust manufacturing capabilities and consistent quality.
  • Auto-injectors

    Product Auto-injectors

    Innovative drug delivery formats designed to support convenience, ease of use and patient-centric care.
  • Azido & Nitroso Impurities Characterization

    Product Azido & Nitroso Impurities Characterization

    Expertise in azido and nitroso impurity characterization, supporting comprehensive quality and analytical requirements for pharmaceutical development.
  • Capsules

    Product Capsules

    A broad capsule portfolio combining quality, consistency and reliable pharmaceutical manufacturing.
  • Carbohydrates

    Product Carbohydrates

    Comprehensive carbohydrate chemistry capabilities supported by experienced teams and a strong focus on quality and scalability.
  • Depot Injections

    Product Depot Injections

    Specialized depot injection capabilities supporting long-acting therapeutic solutions.
  • Genotoxic Impurities Characterization

    Product Genotoxic Impurities Characterization

    Dedicated capabilities for genotoxic impurity characterization, supporting pharmaceutical partners in their quality and development requirements.

MSN Laboratories Resources (1)

  • Brochure MSN corporate overview

    MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.